Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 11 of 11 for “"MASLD/MASH"”.
-
The Role of TMEM41B in VLDL Secretion and the Development and Progression of MASLD
… dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent chronic liver disease characterized by asymptomatic hepatic lipid accumulation. Without treatment, MASLD progresses to metabolic dysfunction associated steatohepatitis (MASH), as excessive lipid droplet (LD) …
-
MODELLING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) WITH HEPATOCYTE-LIKE CELLS DERIVED FROM ADULT LIVER STEM CELLS VIA AIR-LIQUID INTERFACE
… dysfunction-associated steatotic liver disease (MASLD) is a major global cause of chronic liver disease, yet effective therapies are limited due to the lack of physiologically relevant human in vitro models. In this thesis, human liver stem cell (LSC)-derived hepatocyte-like cells (HLCs) …
-
HIGH SALT SUPPLEMENTATION OF A MASH-INDUCING DIET CAUSES LEAN MASH PHENOTYPE WITH INCREASED HEPATIC UREA CYCLE ACTIVITY AND EIF5A HYPUSINATION
MASLD/MASH can occur in lean individuals; however, the environmental triggers and molecular mechanisms underlying lean MASH are unclear, and suitable animal models are lacking. Mice fed a Western diet with liquid fructose (WDF) develops obesity and MASH (obese MASH). In contrast, high salt …
-
Relevanz von GLP-1 Rezeptoragonisten oder SGLT-2 Inhibitoren für die Rekrutierung von Patienten mit MASLD für klinische Studien
… steatotische Lebererkrankung (MASLD) hat in ihrer Prävalenz kontinuierlich zugenommen und betrifft derzeit bis zu 30 % der erwachsenen Weltbevölkerung. Damit ist sie schon heute eine der führenden Indikationen für eine Lebertransplantation. Dementsprechend groß ist das Interesse …
-
Investigation of the Regulation and Pathological Role for Macrophage Sting in MASLD and Insulin Resistance
… dysfunction-associated steatotic liver disease (MASLD), formerly termed as non-alcoholic fatty liver disease (NAFLD), is characterized by the excessive fat deposition in hepatocytes and has the potential to progress to metabolic dysfunction-associated steatohepatitis (MASH) when there is overt …
-
Παγκρεατικές και ηπατικές επιδράσεις των GLP-1 αναλόγων και αγωνιστών υποδοχέων: βιβλιογραφική ανασκόπηση της ασφάλειας και των πιθανών μηχανισμών
… τη μεταβολική δυσλειτουργία που σχετίζεται με τη MASLD/MASH και το HCC. Οι σύγχρονες μελέτες αποδεικνύουν μείωση της συσσώρευσης του ηπατικού λίπους, της φλεγμονής και πιθανότατα της εξέλιξης προς ίνωση και κίρρωση, κυρίως μέσω έμμεσων μεταβολικών μηχανισμών όπως η απώλεια βάρους, η βελτίωση της …
-
Leveraging arginine catabolism to treat metabolic complications
… dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), but intensive lifestyle changes are difficult for many to implement and sustain. Therefore, by identifying and studying fasting-mediated signals, we hope to elicit and convey the …
-
A Sirna-Based Targeted Therapy For Treating Metabolic Dysfunction-Associated Steatotic Liver Disease: A Precision Medicine Approach
… dysfunction-associated steatotic liver disease (MASLD) now affects 30% of the global population. Without intervention, patients with liver steatosis may further develop inflammation and fibrosis, i.e., metabolic-associated steatohepatitis (MASH). Currently, there is only one FDA-approved drug in …
-
Utilising precursors of chemically expanded hepatocytes (pre-cHep) for in vitro modelling of steatotic liver disease
[ A B S T R A C T : R e d a c t e d ]
-
Is there a non-invasive method for diagnosing MASH using ultrasound and artificial intelligence? The MASH-iScan Study
… dysfunction-associated steatotic liver disease (MASLD) now affects approximately 1 in 3 adults globally, and this is set to increase, exacerbating an already epidemic of disease. Metabolic dysfunction-associated steatohepatitis (MASH) is an advanced stage of MASLD and is the driver of fibrosis …
-
Effects of Modulating Hepatic Nrf1 and Nrf2 Activity on Obesity-linked Metabolic Associated Steatohepatitis
… dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease. MASLD’s early steatotic asymptomatic stage is liable to progress to a more severe form known as metabolic dysfunction-associated steatohepatitis (MASH), with advanced complications such as …